In a crossover trial of 20 patients with AChR-positive myasthenia gravis on pyridostigmine, add-on amifampridine 30 mg or 60 mg did not improve the MG Impairment Index vs placebo (differences -1.0 and -1.7; NS); adverse events were more common (60%, 75% vs 30%).
RCTn = 20
Remijn-Nelissen et al. Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial